Coldstream Capital Management Inc. Has $721,000 Holdings in Zoetis Inc. $ZTS

Coldstream Capital Management Inc. cut its stake in Zoetis Inc. (NYSE:ZTS) by 83.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,727 shares of the company’s stock after selling 28,756 shares during the period. Coldstream Capital Management Inc.’s holdings in Zoetis were worth $721,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Global Wealth Strategies & Associates acquired a new position in shares of Zoetis in the 4th quarter worth approximately $25,000. Lodestone Wealth Management LLC acquired a new position in shares of Zoetis in the 4th quarter worth approximately $30,000. KERR FINANCIAL PLANNING Corp acquired a new position in shares of Zoetis in the 3rd quarter worth approximately $31,000. Holos Integrated Wealth LLC acquired a new position in shares of Zoetis in the 4th quarter worth approximately $32,000. Finally, Elyxium Wealth LLC acquired a new position in shares of Zoetis in the 4th quarter worth approximately $32,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ZTS. Argus reissued a “hold” rating on shares of Zoetis in a report on Wednesday. Citigroup dropped their target price on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a report on Monday, May 18th. Morgan Stanley reaffirmed an “overweight” rating and set a $115.00 price target on shares of Zoetis in a report on Friday, May 15th. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Finally, Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Six research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $133.92.

Insider Activity at Zoetis

In other news, Director Paul Bisaro bought 2,000 shares of the stock in a transaction dated Wednesday, May 13th. The stock was bought at an average cost of $75.88 per share, with a total value of $151,760.00. Following the purchase, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Michael B. Mccallister bought 3,000 shares of the stock in a transaction dated Monday, May 11th. The stock was purchased at an average cost of $77.76 per share, with a total value of $233,280.00. Following the completion of the purchase, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired 11,650 shares of company stock valued at $886,384 in the last three months. Corporate insiders own 0.22% of the company’s stock.

Zoetis Trading Down 0.9%

ZTS stock opened at $79.48 on Thursday. The business has a fifty day moving average price of $105.95 and a 200 day moving average price of $117.60. Zoetis Inc. has a fifty-two week low of $72.38 and a fifty-two week high of $172.23. The stock has a market capitalization of $33.32 billion, a price-to-earnings ratio of 13.18, a P/E/G ratio of 1.31 and a beta of 0.87. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same period in the prior year, the business earned $1.48 earnings per share. The company’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Analysts expect that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.